Second-Line Ropeginterferon Alfa-2b Boosts Responses in Essential Thrombocythemia
ZUMA-2 Data Support Earlier-Line Role for Brexu-Cel in High-Risk R/R MCL Subgroups
Second-Line Axi-Cel Is Efficacious, Safe in Real-World Patients With R/R LBCL
New Research Shows Inherited Genetic Variants Increase Risk of Certain Pediatric Cancers